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Introduction 
The 3-hydroxy-3-methylglutaryl coenzyme-A
reductase inhibitors, known as “statins,” are widely
prescribed for dyslipidemia. Recently, statins have
been shown to possess anti-inflammatory and
immunomodulatory “pleiotropic” characteristics1).
Research to clarify clinical advantages of these
effects has been avidly conducted lately. For
example, statins have been shown to reduce
cardiovascular events in patients with coronary
disease2)3) and decrease serum cytokine levels and
reduce neutrophil adhesion in patients undergoing
coronary artery bypass grafting4). In addition, several
animal studies have been conducted to investigate
beneficial effects of statins on septic rats5)6)7).
However, these reports have mainly focused on
effects of statins administered following the
induction of sepsis, and few studies have been
conducted on dose-related effects of statins
administered before the induction of sepsis.
We hypothesized that atorvastatin pretreatment
may show dose-dependent beneficial effects in
endotoxic rats. This study aimed to evaluate dose-
related effects of atorvastatin pretreatment on
mortality and inflammatory responses to endotoxin-
induced shock in rats. 
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Abstract
Purpose - Statins have been prescribed for dyslipidemia for a long time. Till date, several studies have
been conducted on effects of atorvastatin on sepsis; however, dose-related effects have never been
investigated. This study evaluated dose-related effects of atorvastatin on endotoxin-induced shock in rats.
Methods - Fifty-six male Sprague-Dawley rats were randomly assigned to 1 of the 4 different groups
(n = 14 per group): Group C, no medication; group S, oral administration of a small dose of atorvastatin (2
mg/kg/day) for 5 days; group M, oral administration of a medium dose of atorvastatin (5 mg/kg/day) for 5
days; and group L, oral administration of a large dose of atorvastatin (10 mg/kg/day) for 5 days.
Following the pretreatment, endotoxin shock was induced by intravenous administration of
lipopolysaccharide (15 mg/kg). Hemodynamic recordings, arterial blood gas analyses, and plasma
cytokine level measurements were performed regularly. 
Results - Mortality rates between groups S and C differed significantly (7% and 43%, respectively) at
8 h after lipopolysaccharide injection (P < 0.05). In addition, plasma lactate levels between groups S and
C differed significantly at 8 h (P < 0.05). With respect to hemodynamics, the systolic arterial pressure was
considerably higher in group S than in the other groups at 8 h after endotoxin injection.
Conclusions - A small dose of atorvastatin improved mortality rates and inhibited inflammatory
responses to endotoxic shock in rats. These effects were not observed in other doses of atorvastatin,
suggesting dose-related effects of atorvastatin on endotoxic shock. 
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Materials and Methods
The experimental protocol was approved by the
Animal Care Committee of our institution, and care
and handling of the animals were performed in
accordance with the National Institutes of Health
guidelines.
Experimental design and protocol
Fifty-six male Sprague-Dawley rats, weighing 423
(± 26) g {x¯ [± standard deviation (SD)]}, were
included in this study. The rats were randomly
allocated to 1 of the 4 groups (n = 14 per group):
group C, no medication; group S, oral administration
of a small dose of atorvastatin (2 mg/kg/day) for 5
days; group M, oral administration of a medium dose
of atorvastatin (5 mg/kg/day) for 5 days; and group L,
oral administration of a large dose of atorvastatin (10
mg/kg/day) for 5 days. These doses were determined
on the basis of previous reports8)9). After 5 days of
pretreatment, all the rats were anesthetized by
intraperitoneal injection of pentobarbital sodium (30
mg/kg) and ventilated through tracheotomy. The
femoral artery was cannulated to monitor the blood
pressure and draw blood samples. Lactated Ringer
solution containing a muscle relaxant (pancuronium
bromide, 0.02 mg/mL) and pentobarbital sodium (0.5
mg/mL) were continuously infused at a rate of 10
mL/kg/h through the femoral vein cannula. The rats
were connected to a pressure-controlled ventilator
(Servo 900B; Siemens-Elema, Solna, Sweden) that
delivered 21% oxygen at a frequency of 28
breaths/min with an inspiratory:expiratory ratio of 1:1.
The rats were rested on a table for approximately 15
min for hemodynamic stabilization. Following this,
baseline recordings of the heart rate (HR) and systolic
arterial pressure (SAP) were obtained. This method of
animal preparation was reported previously.10)
Endotoxic shock was induced by intravenous
injection of endotoxin (15 mg/kg). The rats did not
receive any therapy before, during, or following
shock induction. The rectal body temperature was
maintained between 36℃ and 38℃ with a heating
pad on the table. 
The survival rate was observed for 8 h after
endotoxin injection. Arterial blood samples (0.25
mL) were obtained to measure pH, partial pressure of
arterial carbon dioxide, partial pressure of arterial
oxygen, and base excess and lactate levels at
baseline, 1, 2, 3, 4, 5, and 8 h. Additional arterial
blood samples (1.5 mL) were obtained to measure
plasma cytokine [tumor necrosis factor (TNF)-alpha
and interleukin (IL)-6] levels at baseline, 2, 4, and 5
h. Enzyme-linked immunosorbent assay kits
(BioSource, Camarillo, CA, USA) were used to
measure cytokine (TNF-alpha and IL-6) levels.
Statistical analysis
Data are presented as the mean (± SD).
Differences between groups at baseline were
analyzed by 1-way analysis of variance followed by
a post hoc test (the Dunnett method). Differences
between groups at different times were analyzed by
2-way analysis of variance with repeated measures
































































   35±15.1† 
Baseline 2h 4h 8h
   Values are expressed as X‾±SD. pHa = arterial pH, PaO2 = partial pressure of arterial oxygen, 
PaCO2 = partial pressure of arterial carbon dioxide, SD = standard deviation. ＊P<0.05 Group S 
v.s. Group C, †P<0.05 Group S v.s. Group L, ‡P<0.05 Group M v.s. Group MC, §P<0.05 Group 
C v.s. Group L
Table 1. Arterial blood gas analyses at baseline and after endotoxin injection
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followed by a post hoc test (the Bonferroni method).
Survival rates among the groups were compared
using the Kaplan-Meier and Mantel-Cox tests.
Significance was defined as P value <0.05. SPSS




No significant differences in the baseline HR and
SAP were noted among the 4 groups (Fig. 1). Both
HR and SAP continuously decreased after the
injection in all groups. SAP was significantly higher
in group S than in groups C and L at 8 h after
endotoxin injection (P<0.05). HRs were significantly
higher in group S than in groups C and L at 8 h after
endotoxin injection (P<0.05). 
Survival rates
Survival rates at 8 h were 57%, 93%, 64%, and
43% for groups C, S, M, and L, respectively (Fig. 2).
The survival rate of group S was significantly higher
than that of groups C and L at 8h (P < 0.05).
Blood gases
Results of blood gas analyses are shown in Table 1.
pHa was significantly lower in group S compared the
other 3 groups  at baseline (P<0.05). At 8h, it was
higher in groups C compared with other 3 groups
(P<0.05). PaO2 did not differ significantly among all
groups at baseline and 8h. PaCO2 was significantly
higher in group S compared with the other 3 groups
at baseline and 8h (P<0.05).
Lactate levels and base excess levels
No significant difference was observed in the
baseline lactate and base excess levels among the 4
groups (Fig. 3). Metabolic acidosis, as indicted by
the increase in serum lactate levels and decrease in
base excess levels, developed in all the groups during
the experiment; however, base excess levels in group
S were significantly higher than those in the other
groups at 8h after the injection (Fig. 3, A). Lactate
levels in group S were significantly lower than those
in the other groups at 8h (P < 0.05) (Fig. 3, B).
Plasma cytokine levels
Plasma cytokine levels were measured in groups
C, S, and L (Fig. 4). Baseline values of the 3 groups
were similar. TNF-alpha and IL-6 levels increased in
all the 3 groups after endotoxin injection. However,
there were no significant differences in any of these
cytokines among the 3 groups at 5h.
Figure 1. Hemodynamic changes in systolic arterial pressure (A)
and heart rates (B) from baseline (0h) up to 8 h after
endotoxin injection. group C (control), Group L
(large dose), group M (medium dose), group S
(small dose)
A: At 8h, ＊ P<0.05 Group S v.s. Group C, † P<0.05 Group S
v.s. Group L
B: At 8h, ＊ P<0.05 Group S v.s. Group C, † P<0.05 Group S
v.s. Group L
Figure 2. Survival rates after endotoxin injection. group C
(control), Group L (large dose), group M (medium
dose), group S (small dose)
At 8h, ＊ P<0.05 Group S v.s. Group C, † P<0.05 Group S v.s.
Group L
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Discussion
Endotoxemia causes hypotension and metabolic
acidosis in addition to triggering increases in plasma
proinflammatory cytokine levels, which lead to high
mortality rates at 8 h after endotoxin injection. In the
present study, oral administration of a small dose of
atorvastatin inhibited the development of severe
hypotension and metabolic acidosis, resulting in
lower mortality rates. However, this beneficial effect
was not observed with a medium or large dose of the
same agent. Of note, the anti-inflammatory effect
was exerted only with a small dose and not with
larger doses. 
Several studies have recently demonstrated that
statins possess anti-inflammatory and immunomodulatory
“pleiotropic” characteristics. Ando et al. showed that
pretreatment with cerivastatin reduced mortality rates
in endotoxic mice5). Merx et al. revealed that
pretreatment with simvastatin improved survival in
septic mice6). They also showed that post-treatment
with statins improved survival the following year7).
However, there are few studies on dose-related
effects of atorvastatin pretreatment on sepsis. The
present study demonstrated that a small dose of
atorvastatin exerts anti-inflammatory effects in
endotoxic rats; however, a medium or large dose
does not. These findings suggest that atorvastatin
may have dose-related anti-inflammatory effects on
sepsis.
Figure 3. Baseline values of plasma lactate concentrations (A)
and base excess (B), and their changes after endotoxin
injection. group C (control), Group L (large dose),
group M (medium dose), group S (small dose)
A: At 8h, ＊ P<0.05 Group S v.s. Group C, † P<0.05 Group S
v.s. Group L, § P<0.05 Group S v.s. Group M
B: At 8h, ＊ P<0.05 Group S v.s. Group C, † P<0.05 Group S
v.s. Group L, § P<0.05 Group S v.s. Group M
Figure 4. Serum cytokine levels measured after endotoxin
injection. group C (control), Group L (large dose),
group S (small dose)
Many studies have shown that various types of
statins exert different degrees of anti-inflammatory
effect; however, few studies have been conducted to
investigate dose-related effects of statins using animal
models. Medeiros et al. showed that a small dose of
atorvastatin reduced mucosal damage and
inflammation in 5-fluorouracil-induced oral mucositis
and that higher doses of atorvastatin were associated
with hepatotoxicity and amplified leukopenia11). Our
findings suggest that an appropriate dose of
atorvastatin may improve mortality rates and inhibit
inflammatory responses in sepsis, however, higher
doses may not have the same effect. This may be due
to the fact that deleterious effects of atorvastatin, such
as rhabdomyolysis, manifest themselves in higher
serum levels and therefore negating the beneficial
effects of atorvastatin.
Recent studies have demonstrated that statins
inhibit the elevation of proinflammatory cytokines
such as TNF-alpha and IL-1-beta in vitro and in
vivo12)-14). One possible mechanism of these effects is
that statin reduces inducible nitric oxide synthase
expression by blocking the transcription factors
nuclear factor kB and signal transducer/activator of
transcription-115). However, the present study failed to
show a dose-dependent anti-inflammatory effect of
atorvastatin with respect to TNF-alpha and IL-6
levels. However, in this study, we did not evaluate
other types of cytokines, such as IL-1 beta, which
might have contributed to the findings of this study.
Further investigations are necessary to determine the
optimal dosage and timing of administration of
atorvastatin that will reduce cytokine levels.
Whether atorvastatin shows the same degree of
anti-inflammatory effects in different sepsis models,
including cecal ligation and puncture as well as
intravenous injection of bacteria, remains to be
elucidated. Endotoxic shock manifests itself
differently depending on the clinical situation;
therefore, further studies are required to understand
these situations.
Several clinical studies have demonstrated that
atorvastatin pretreatment inhibits systemic
inflammatory responses after major surgery. Chello et
al.16) and Pan et al.17) showed that statin pretreatment
improves perioperative mortality and decreases
cytokine levels following coronary bypass surgery.
Raux et al. reported that oral administration of statin
inhibits the development of an aneurysm sac after
elective endovascular aneurysm repair18). These
findings and those of the present study suggest that
statins have beneficial effects not only
intraoperatively but also postoperatively on patients
undergoing major surgery.
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